Limits...
The impact of Anastrazole and Letrozole on the metabolic profile in an experimental animal model.

Boutas I, Pergialiotis V, Salakos N, Agrogiannis G, Konstantopoulos P, Korou LM, Kalampokas T, Gregoriou O, Creatsas G, Perrea D - Sci Rep (2015)

Bottom Line: Previous studies suggested a possible association with metabolic and liver adverse effects.Their results are conflicting.The OA also significantly differed from the OL (p = 0.50).

View Article: PubMed Central - PubMed

Affiliation: Second Department of Obstetrics and Gynecology, University of Athens, Vas. Sofias 76, Athens, 11528, Greece.

ABSTRACT
Anastrazole and Letrozole are used as endocrine therapy for breast cancer patients. Previous studies suggested a possible association with metabolic and liver adverse effects. Their results are conflicting. Fifty-five 4-week-old female Wistar rats were allocated in 4 groups 1) ovariectomy control (OC), 2) ovariectomy-Anastrazole (OA) 3) ovariectomy -Letrozole (OL), 4) control. Serum glucose, cholesterol, triglycerides, HDL-c and LDL-c were measured at baseline, 2 and 4 months. At the end, the animals' liver were dissected for pathology. At 4 months, total cholesterol differed among the OC and OL groups (p = 0.15) and the control and OL groups (p = 0.12). LDL-C differed between the control and OC groups (p = 0.015) as well as between the control and OA (p =0 .015) and OL groups (p = 0.002). OC group triglycerides, differed from those of the OL group (p =0 .002) and the control group (p = 0.007). The OA also significantly differed from the OL (p = 0.50). Liver pathology analysis revealed differences among groups with favored mild steatosis and ballooning. Anastrazole and Letrozole seem to negatively influence the lipid profile in our experimental model. This information should be taken in caution by medical oncologists when addressing patients with altered lipid metabolism.

No MeSH data available.


Related in: MedlinePlus

Representative liver figures, eosin-hematoxylin staining, 200× original magnification.(A) normal liver architecture. (B) small focus of periportal chronic inflammatory infiltrate (arrow). (C) moderate—score 2—parenchymal steatosis with panacinar distribution (arrows). (D) mild—score 1—steatosis (arrow). (E) moderate number of ballooned hepatocytes—score 2—(arrows). (F) focal hepatocyte ballooning—score 1—(arrow) along with sparse lipid droplets (thick arrow).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4664924&req=5

f2: Representative liver figures, eosin-hematoxylin staining, 200× original magnification.(A) normal liver architecture. (B) small focus of periportal chronic inflammatory infiltrate (arrow). (C) moderate—score 2—parenchymal steatosis with panacinar distribution (arrows). (D) mild—score 1—steatosis (arrow). (E) moderate number of ballooned hepatocytes—score 2—(arrows). (F) focal hepatocyte ballooning—score 1—(arrow) along with sparse lipid droplets (thick arrow).

Mentions: Hematoxylin-eosin stained liver samples obtained from animals of Letrozole and Anastrazole groups showed signs of hepatic steatosis and ballooning (Fig. 2, Table 3). The grade of fatty liver disease was considered as “mild” in eight of the eleven rats in Anastrazole group. In nine of the twelve rats of the Letrozole group, the grade of steatosis was considered as “mild”, in two animals of this group the grade of steatosis was characterized as “moderate” while only one animal of this group presented normal liver architecture. In both control and ovariectomized control groups, “mild” steatosis was detected in one animal per group. No statistically significant differences were detected in the grade of steatosis between the Letrozole and Anastrazole groups (p = 0.331) although liver architecture was more disturbed in Letrozole treated rats. Hepatocellular degeneration (ballooning) of grade 1 was confirmed in five of the twelve animals of Letrozole group and in two of the eleven animals of Anastrazole group. Ballooning of grade 2 was detected in two Letrozole treated rats. Ballooning was not observed in any animal of the control or ovariectomized control groups. Neither portal nor lobular inflammation were detected in the liver lesions of all the animals studied.


The impact of Anastrazole and Letrozole on the metabolic profile in an experimental animal model.

Boutas I, Pergialiotis V, Salakos N, Agrogiannis G, Konstantopoulos P, Korou LM, Kalampokas T, Gregoriou O, Creatsas G, Perrea D - Sci Rep (2015)

Representative liver figures, eosin-hematoxylin staining, 200× original magnification.(A) normal liver architecture. (B) small focus of periportal chronic inflammatory infiltrate (arrow). (C) moderate—score 2—parenchymal steatosis with panacinar distribution (arrows). (D) mild—score 1—steatosis (arrow). (E) moderate number of ballooned hepatocytes—score 2—(arrows). (F) focal hepatocyte ballooning—score 1—(arrow) along with sparse lipid droplets (thick arrow).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4664924&req=5

f2: Representative liver figures, eosin-hematoxylin staining, 200× original magnification.(A) normal liver architecture. (B) small focus of periportal chronic inflammatory infiltrate (arrow). (C) moderate—score 2—parenchymal steatosis with panacinar distribution (arrows). (D) mild—score 1—steatosis (arrow). (E) moderate number of ballooned hepatocytes—score 2—(arrows). (F) focal hepatocyte ballooning—score 1—(arrow) along with sparse lipid droplets (thick arrow).
Mentions: Hematoxylin-eosin stained liver samples obtained from animals of Letrozole and Anastrazole groups showed signs of hepatic steatosis and ballooning (Fig. 2, Table 3). The grade of fatty liver disease was considered as “mild” in eight of the eleven rats in Anastrazole group. In nine of the twelve rats of the Letrozole group, the grade of steatosis was considered as “mild”, in two animals of this group the grade of steatosis was characterized as “moderate” while only one animal of this group presented normal liver architecture. In both control and ovariectomized control groups, “mild” steatosis was detected in one animal per group. No statistically significant differences were detected in the grade of steatosis between the Letrozole and Anastrazole groups (p = 0.331) although liver architecture was more disturbed in Letrozole treated rats. Hepatocellular degeneration (ballooning) of grade 1 was confirmed in five of the twelve animals of Letrozole group and in two of the eleven animals of Anastrazole group. Ballooning of grade 2 was detected in two Letrozole treated rats. Ballooning was not observed in any animal of the control or ovariectomized control groups. Neither portal nor lobular inflammation were detected in the liver lesions of all the animals studied.

Bottom Line: Previous studies suggested a possible association with metabolic and liver adverse effects.Their results are conflicting.The OA also significantly differed from the OL (p = 0.50).

View Article: PubMed Central - PubMed

Affiliation: Second Department of Obstetrics and Gynecology, University of Athens, Vas. Sofias 76, Athens, 11528, Greece.

ABSTRACT
Anastrazole and Letrozole are used as endocrine therapy for breast cancer patients. Previous studies suggested a possible association with metabolic and liver adverse effects. Their results are conflicting. Fifty-five 4-week-old female Wistar rats were allocated in 4 groups 1) ovariectomy control (OC), 2) ovariectomy-Anastrazole (OA) 3) ovariectomy -Letrozole (OL), 4) control. Serum glucose, cholesterol, triglycerides, HDL-c and LDL-c were measured at baseline, 2 and 4 months. At the end, the animals' liver were dissected for pathology. At 4 months, total cholesterol differed among the OC and OL groups (p = 0.15) and the control and OL groups (p = 0.12). LDL-C differed between the control and OC groups (p = 0.015) as well as between the control and OA (p =0 .015) and OL groups (p = 0.002). OC group triglycerides, differed from those of the OL group (p =0 .002) and the control group (p = 0.007). The OA also significantly differed from the OL (p = 0.50). Liver pathology analysis revealed differences among groups with favored mild steatosis and ballooning. Anastrazole and Letrozole seem to negatively influence the lipid profile in our experimental model. This information should be taken in caution by medical oncologists when addressing patients with altered lipid metabolism.

No MeSH data available.


Related in: MedlinePlus